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Abstract: Cleavage of Gag and Gag-Pol precursors by the viral protease is an essential 
step in the replication cycle of HIV. Protease inhibitors, which compete with natural 
cleavage sites, strongly impair viral infectivity and have proven to be highly valuable in 
the treatment of HIV-infected subjects. However, as with all other antiretroviral drugs, the 
clinical benefit of protease inhibitors can be compromised by resistance. One key feature 
of HIV resistance to protease inhibitors is that the mutations that promote resistance are 
not only located in the protease itself, but also in some of its natural substrates. The best 
documented resistance-associated substrate mutations are located in, or near, the cleavage 
sites in the NC/SP2/p6 region of Gag. These mutations improve interactions between the 
substrate and the mutated enzyme and correspondingly increase cleavage. Initially 
described as compensatory mutations able to partially correct the loss of viral fitness that 
results from protease mutations, changes in Gag are now recognized as being directly 
involved in resistance. Besides NC/SP2/p6 mutations, polymorphisms in other regions of 
Gag have been found to exert various effects on viral fitness and or resistance, but their 
importance deserves further evaluation. 
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1. Introduction 
Protease inhibitors (PIs) are among the most active antiretroviral drugs currently used in the 
treatment of HIV infection. These compounds, which mimic the natural Gag and Gag-Pol substrates of 
the HIV protease, inhibit the proteolytic activity of the enzyme and exert a powerful inhibitory effect 
on HIV replication both in vitro and in vivo. In a large majority of treated patients, combinations of 
antiretroviral drugs that include PIs result in complete suppression of active HIV replication, and in 
remarkable recovery of immunodeficiency and reduction of AIDS-related mortality. However, as with 
all other antiretroviral drugs, failure by PIs to fully suppress HIV replication leads to the development 
of viral resistance. A unique feature of HIV resistance to PIs is the fact that resistance mutations not 
only arise in the protease itself – the direct target of the inhibitors – but also in some of the natural 
substrates of the protease – the Gag cleavage sites. We will review here the evidence that Gag cleavage 
site mutations are an important element of HIV resistance to PIs and discuss the mechanisms and 
implications of this phenomenon. 
2. The HIV-1 protease and its natural substrates 
The HIV protease is required to cleave the Gag and Gag-Pol polyproteins into their final functional 
protein products, leading to the assembly of a fully mature and infectious viral particle. The protease is 
encoded as part of the Gag-Pol polyprotein itself and becomes activated following a dimerization event 
that is only possible at sites where the concentration of Gag-Pol polyproteins is high, essentially at the 
site of virion assembly and budding. The protease domain cleaves itself out of the Gag-Pol polyprotein 
to constitute a symmetrically assembled homodimer, in which the substrate-binding site is a central, 
symmetrical cavity that is equally defined by each of the two subunits of the homodimer. Proteolytic 
cleavage of Gag and Gag-Pol polyproteins by the protease can be viewed as a switch from a 
configuration of the polyproteins that favors assembly and budding at the cell surface, to a 
configuration that promotes reassembly of a free mature capsid structure that can be released into the 
cytoplasm of the target cell, where it will deliver the fully functional replicative machinery of the 
virus. Proper assembly of this mature capsid structure requires that cleavage of the Gag and Gag-Pol 
polyproteins by the protease occur in an ordered and controlled manner [1-3]. 
The order of cleavage of the Gag polyprotein is depicted in Figure 1. The first cleavage event 
separates the nucleocapsid protein (NC) from the capsid (CA) protein downstream of a 14-amino acid 
linker peptide termed SP1 (spacer peptide 1, formerly termed p2). Next, the CA protein is separated 
from the matrix (MA) protein, which remains associated with the virion membrane. This event that is 
almost simultaneous to the release of the C-terminal p6 Gag protein, downstream of another linker 
peptide located between NC and p6, termed SP2 (spacer peptide 2, formerly termed p1). Finally, the 
two linker peptides SP1 and SP2 are trimmed from the CA and NC proteins, respectively. The SP1 
spacer peptide appears to play an important part in the overall maturation of Gag [4,5] and in the 
proper regulation of the ordered cleavage of Gag by the protease  [3,6], however the role of SP2 
remains unclear. An important factor in the ordered cleavage of Gag by the protease is the amino acid 
sequence of the cleavage site substrates [7]. These natural substrates are constituted of seven amino 
acids, whose position relative to the cleaved peptide bond are designated from N to C terminus:   Viruses 2010, 2                              
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P4-P3-P2-P1 / P1’-P2’-P3’, with cleavage occurring between P1 and P1’ [7]. The amino acid sequence 
of the different cleavage site substrates within Gag strikingly differs from one site to another, some 
sites (most notably the SP1/NC site) being even remarkably polymorphic between HIV-1 clinical 
strains [8-12]. The difference in the amino acid sequence of these different substrates explains at least 
in part their differential rate of cleavage by the protease [2,7]. Interestingly, in spite of their marked 
sequence diversity, there is a strong similarity in the three-dimensional structure of these peptides in 
Gag [13,14], which explains why they all constitute strong and specific substrates for this enzyme, 
albeit with different cleavage rate efficiencies. 
Figure 1. The ordered cleavage of the HIV Gag polyprotein precursor. The protein 
composition of the HIV Gag precursor is shown: colored boxes represent the internal 
structural proteins (matrix: MA, capsid: CA and nucleocapsid: NC), the protein p6 and the 
spacer peptides (SP1 and SP2). Arrows point to the position of cleavage sites. The 
sequences of the seven residues encompassing each cleavage site are indicated, with a 
slash representing the position of the scissile bond. Numbers indicate the decreases in the 
estimated rates of cleavage (from reference [3]), with the initial event between SP1 and NC 
set to a value of 1. 
 
 
3. HIV resistance to PIs: protease mutations 
HIV resistance to PIs is the consequence of accumulation of amino acid substitutions in the 
protease. During viral escape in vitro or in vivo, mutations accumulate gradually, leading to a 
progressive increase in the level of resistance [15,16]. Some mutations affect amino acids that are an 
integral part of the substrate binding domain of the enzyme: these mutations, often termed primary 
mutations, generally initiate the process of resistance evolution, and can differ from one PI to another. 
One of the most characteristic primary mutations is the substitution V82A, which is seen in most 
viruses having developed resistance to various PIs. Interestingly, this mutation modifies a strong point 
of contact between the enzyme and the inhibitors, but only one of the two valine residues at position 
82 in the homodimeric protease is important for contact with the natural substrates [17]. Subsequently, 
secondary mutations are selected, which involve amino acids located away from the substrate-binding 
cavity. These secondary mutations are less drug-specific than primary mutations but are nonetheless Viruses 2010, 2                              
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critical for high-level resistance. Both primary and secondary mutations modify the shape and size of 
the substrate-binding cavity of the HIV protease, thereby reducing the affinity and the inhibitory 
potential of the inhibitors [18-20].  
Overall, both primary and secondary resistance mutations appear to enlarge the substrate-binding 
cavity of the protease [18]. This enlargement seems to have more important consequences on the 
binding of the inhibitors, most of which are dependent upon a strong and tight interaction with the 
active site of the enzyme, than on the binding of the natural substrates of the protease in Gag and Gag-
Pol. Indeed, Gag and Pol precursors interact less tightly with the enzyme [17-20], a property that is 
consistent with their ordered and regulated cleavage by the protease. With a few exceptions, strong and 
radical changes in inhibitor affinity cannot be achieved by single changes in the protease, and high 
level resistance requires subtle distortions of the substrate binding site that are both efficient in terms 
of resistance and tolerable for enzyme function.  
4. HIV resistance to protease inhibitors and viral fitness 
In spite of the subtle and gradual resistance evolution process described above, resistance to PIs is 
always a compromise between resistance and enzyme function. In fact, most PI-resistant viral strains 
display some extent of impairment of protease function and corresponding defects in replicative 
capacity or fitness [21-23]. Initial studies have suggested that only primary mutations had an impact on 
enzyme function and viral fitness, in view of their situation within the substrate binding cavity, and 
that secondary mutations were able to fully restore enzyme function and viral fitness [24]. In fact, most 
studies on clinical strains having developed resistance to protease inhibitors show that almost all 
viruses with high-level resistance display various degrees of fitness loss, even in the presence of 
multiple secondary mutations [21,22,25,26]. Interestingly, loss of protease function and loss of fitness 
can differ markedly from one resistant virus to another, with both differences in the levels of fitness 
impairment and differences in the nature of the cleavage defects in Gag or in Gag-Pol [21-23,26-28]. 
Therefore, secondary mutations in the protease may, in some instances, be quite effective in 
compensating for losses of fitness at early stages of protease resistance evolution, but strong 
pharmacological pressure by PIs, requiring further accumulation of resistance mutations and high-level 
resistance, almost always reduce viral fitness [25]. Resistance-associated loss of fitness is generally 
modest (two to 10-fold) in comparison with the increase in resistance (often >100-fold), explaining 
that natural selection by high concentrations of PIs would always favor highly resistant viruses even at 
the expense of some loss of fitness [21,25]. In this context, however, it was found that viral fitness and 
resistance were not only affected by mutations in the protease itself, but that both parameters were also 
strongly affected by mutations in Gag cleavage sites. 
5. Cleavage site mutations as compensatory changes for resistance-associated loss of viral fitness 
Initial observations of mutations in Gag cleavage sites during selection for resistance to PIs were 
made by Doyon et al. [29] in viruses subjected to in vitro selection by experimental inhibitors BILA 
1906 BS and BILA 2185 BS. The mutations were located within the two cleavage sites that define the 
SP2 peptide between NC and Gag p6 (Figure 2). In one experiment with BILA 1906 BS, an L to F 
substitution at position P1’ of the SP2/p6 cleavage site was observed, a mutation designated L449F Viruses 2010, 2                              
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when numbered according to the whole Gag polyprotein amino acid sequence. This mutation was 
found to emerge shortly after selection of three mutations in the protease, including the mutation I84V. 
In a second experiment with BILA 2185 BS, mutation L449F was again selected, but was shortly 
followed by emergence of dual mutations Q430R and A431V at positions P3 and P2, respectively, of 
the NC/SP2 site. Interestingly, the presence of these mutations had a clear effect on virus replication 
kinetics, but no changes in IC50 were observed. 
Figure 2. Frequently observed mutations at the NC/SP2/p6 cleavage sites. A. Gag 
mutations frequently observed in isolates from protease inhibitor-treated patients are 
shown in red, with arrows indicating their position in the Gag polyprotein. Protease 
mutations often found in association with these Gag mutations are shown in purple circles. 
B. Amino acid sequence of the subtype-B consensus, encompassing the NC/SP2/p6 
cleavage sites in Gag. Arrows indicate the nucleocapsid (NC), SP2 and p6 domains. The 
first set of five sequences below the consensus illustrates Gag mutations frequently 
observed in virus isolates from treated patients. The following set of four sequences shows 
the position of Gag mutations obtained from in vitro studies with experimental protease 
inhibitors. Dots indicate amino acid identity to the subtype-B consensus. 
 
 
Mutations in Gag cleavage site were also found in viruses from treated patients. In a series of 
samples from indinavir-treated subjects in whom treatment failed to control HIV replication,   
Zhang et al. [30] observed early emergence of mutation A431V in the NC/SP2 cleavage site in three Viruses 2010, 2                              
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patients, while substitution L449F in SP2/p6 was seen at a later time point in one patient. In another 
study involving 16 patients having failed treatment by ritonavir or saquinavir, Mammano et al. [28] 
observed the presence of the mutation A431V in NC/SP2 in two instances and mutation of L449F in 
SP2/p6 was seen in one case. Further study on the replicative capacity of recombinant proviral clones 
carrying either Gag-protease or protease alone from these three viruses revealed that the mutated Gag 
sequences were able to compensate at least partially for the loss of fitness conferred by the cognate 
mutated proteases. The rescue of virus replicative capacity was associated with, and supposedly due to, 
improved cleavage at the mutated site by resistant proteases. Thus, it became accepted that the role of 
Gag cleavage site mutations was essentially related to viral replicative capacity or fitness. 
Following these initial observations, several studies pointed to the importance of Gag cleavage site 
mutations in the evolution of HIV resistance to PIs [9,31-36]. New mutations were observed, some of 
which are located in close proximity – although not within the canonical seven amino acid sequence – 
of the cleavage sites, in particular the mutation I437V downstream of the NC/SP2 site, and mutation 
P453L downstream of the SP2/p6 site  [33,34]. Strong associations between some of these Gag 
mutations and specific protease resistance mutations were seen. Indeed, while Gag mutations A431V 
and I437V are almost constantly associated with protease resistance genotypes that include the 
mutation V82A, the Gag mutation L449F is most frequently seen in association with I84V in the 
protease [8,35]. It has even been suggested, but not clearly demonstrated, that emergence of the I84V 
mutation could actually be favored by the preexisting mutation L449F in Gag [8]. Mutation P453L, 
which can be seen in some primary HIV-1 sequences from treatment-naïve patients, can nonetheless 
emerge in association with the mutation I84V or with the amprenavir-specific mutation I50V [34]. 
These associations were validated and extended in a relatively large survey (500 patients) that 
compared Gag cleavage site sequences from treatment-naive and -experienced patients [37]. The most 
frequent therapy-associated mutations in the NC/SP2 cleavage site (A431V and I437V) were observed 
in association with protease mutations at positions 82 and 54, while leading mutations at the SP2/P6 
cleavage site (L449F and P453L) were found in the context of protease mutations D30N or I84V. A 
detailed table of the individual frequency of association can be found in the original article  [37]. 
Although some viruses from this and other studies (e.g., [31]) do not fit into this simple pattern, such a 
general association rule summarizes data from several reports. Tighter associations should not be 
expected, because of the multiple parameters that govern the emergence of mutations in PR and Gag, 
such as the specific inhibitor used, the order of exposure to different inhibitors, the duration of 
treatment and pre-existing Gag polymorphisms. Finally, there is no apparent mechanistic or 
evolutionary conflict between mutations affecting the NC/SP2 or SP2/p6 sites. Some data, however, 
suggest that the mutations A431V and I437V, both being favored in the context of the protease 
mutation V82A, are not seen on the same genomes and may be incompatible with each other [38]. 
6. Cleavage site mutations as resistance mutations 
Besides the well documented effect of Gag cleavage site mutations on resistance-associated loss of 
viral fitness, evidence has been accumulating that these mutations could also directly affect HIV 
susceptibility to PIs in a manner that is independent of their effect on fitness. In their 1997 study, 
Zhang et al. [30] observed that the presence of the mutation A431V in NC/SP2 could improve the Viruses 2010, 2                              
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kinetics of viral replication not only in the absence of indinavir, but also in the presence of moderate 
concentrations of that drug. Similarly, Carron de la Carrière et al. [27] observed that the presence of 
the same A431V mutation strongly improved the selective advantage profile of some protease mutants 
in the presence of ritonavir, a parameter that reflects the ability of viral variants to outgrow wild-type 
virus according to the concentration of drug in the culture. In line with these earlier findings,   
Maguire et al. [34], studying the effect of Gag mutation P453L in viruses carrying the amprenavir-
specific I50V protease mutation, again observed that beyond merely correcting viral fitness, the Gag 
mutation could also significantly increase the IC50 of amprenavir in these mutants. Finally, Prado  
et al. [39] reported that the Gag mutation L449F, in the context of amprenavir-selected mutations 
L10F/I84V, increased phenotypic resistance to all PI tested. In these four studies, however, the extent 
to which the increase in resistance was dependent or independent of the effect of Gag mutations on 
viral fitness was not clearly determined. This point was solved by two recent studies [40,41], which 
clearly demonstrated that Gag cleavage site mutations, independently of their role in viral fitness, 
should be considered as authentic PI resistance mutations. 
In a study by Nijhuis et al. [41], a laboratory strain of HIV-1 was subjected to selection through 
repeated cell culture passaging in the presence of increasing concentrations of an experimental PI, 
RO033-4649. Remarkably, viral variants selected by this process did not carry any resistance 
mutations in the protease. Instead, these variants exhibited mutations in the SP2 spacer peptide, K436E 
and I437T or V. Introduction of these mutations in combination in a wild-type reference proviral clone 
showed a clear, although moderate, increase in the IC50 of RO033-4649 and of other PIs, thereby 
demonstrating the direct impact of Gag mutations on resistance to a wide range of protease inhibitors, 
in the absence of protease mutations. The impact of Gag cleavage site mutations in PI resistance was 
further emphasized in a study by Dam et al. [40], examining the phenotype of different recombinant 
viral clones carrying different Gag or Gag-Pol segments from highly evolved viruses that had 
accumulated multiple PI resistance mutations in treated patients. All of these primary viral sequences 
also carried one or more of the characteristic mutations in the NC/SP2/p6 Gag cleavage sites as 
described in Figure 2. In this study, it was found that the association of mutated Gag sequences 
together with mutated protease sequences produced markedly higher IC50 levels and fitness values. 
This effect was fully recapitulated by a segment of the viral genome expressing the NC/SP2/p6 region 
of Gag (Figure 3). Strikingly, reversion of individual cleavage site mutations A431V or I437V in these 
viruses markedly reduced their level of resistance, but had only a marginal effect on fitness, strongly 
suggesting that these mutations were indeed essentially acting by themselves as authentic resistance 
mutations. In contrast, their benefit in terms of viral fitness appeared more complex, and while the 
mutations within cleavage site sequences such as A431V or I437V certainly exert a positive impact on 
fitness at early stages of resistance evolution, this effect may be diverted or confounded by further  
co-evolution and adaptation of as yet poorly defined determinants in the NC/SP2/p6 region.  Viruses 2010, 2                              
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Figure 3. Effect of Gag on protease inhibitor resistance. Different combinations of Gag 
and Pol sequences from two protease inhibitor-experienced patients (VIS09 and VIS13) 
were used to replace the corresponding regions from an HIV molecular clone (NL4.3). The 
fold-increase in IC50 (as compared to wild type NL4.3 virus) for the protease inhibitor 
Atazanavir (ATV) is shown on the Y-axis. For both individuals, patient-derived Gag 
sequences (Gag-PR-RT, and NC-PR-RT) were required for high-level resistance, as the 
clones carrying only Pol from patient (PR-RT alone) displayed significantly lower 
resistance levels. In particular, the C-terminus of Gag (encompassing the NC/SP2/p6 
cleavage sites) was sufficient to confer high-level resistance in the context of patient-
derived Pol (NC-PR-RT). Primary Gag sequences from these two patients, expressed in the 
absence of protease mutations (Gag-alone), did not confer statistically significant 
resistance to ATV. Data are from the study in reference [38]. 
 
 
7. Mechanisms of action of Gag cleavage site mutations 
The mechanisms through which Gag cleavage site mutations can increase resistance and improve 
viral fitness are yet to be fully understood. These mechanisms are centered on three key questions.  
The first question, addressing how single mutations act locally on the interaction between the 
cleavage site substrate and the protease, has been partially answered by structural crystallographic 
studies of wild-type or mutated substrates in the presence of wild-type or mutated protease. In 
particular, it is well understood how the A431V mutation can improve cleavage of the NC/SP2 site by 
a protease bearing the V82A mutation (Figure 4) [17]. The smaller alanine residue at position 82 in the 
protease, compared to wild-type valine, opens a space between the enzyme and protease inhibitors, 
thereby decreasing affinity of the inhibitor for the enzyme and producing resistance. This change, Viruses 2010, 2                              
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however, also reduces to some extent the contact between the protease and the NC/SP2 substrate. As 
shown in Figure 4, the A431V mutation creates a protrusion of the NC/SP2 peptide in a space within 
the substrate-binding domain that is not naturally occupied by the substrate. Interestingly, this 
structural change does not involve any of the substrate residues that are in direct contact with the 
amino acid at position 82, but instead creates a different, alternative contact between the enzyme and 
substrate that compensates for the loss of contact resulting from the protease mutation. This model, 
following which substrate changes can fill gaps between substrate and mutated enzyme and thereby 
improve cleavage, provides a highly credible explanation for the effect of Gag cleavage site mutations 
on viral fitness and is likely to apply to other cleavage site mutations observed in PI-resistant viruses. 
It is corroborated by observations that cleavage sites carrying the characteristic mutations described 
earlier behave as better substrates for the protease in vitro, whether mutated or wild-type [29]. This 
improvement in cleavage cannot be selected for in the absence of PIs, most likely in view of the fact 
that cleavage at the NC/SP2/p6 sites needs to be fully balanced with cleavage at other sites, and that 
viruses with increased NC/SP2/p6 cleavage efficiency may not necessarily be advantaged in the 
absence of PIs and/or in the context of a wild-type protease. 
The second question that needs to be answered is why most PI resistance-associated Gag mutations 
are clustered around the SP2 peptide. Coren et al. [42] have evaluated the replicative importance of 
cleavage at the NC/SP2 and at the SP2/p6 sites in viruses carrying mutations that reduced cleavage at 
these sites. Surprisingly, full obliteration of NC/SP2 cleavage in one of these mutant viruses did not 
affect HIV-1 replication. This finding strongly contrasts with the observations of Dam et al. [40], 
where it appeared that the extent of cleavage at this site, as measured by the amount of mature NC 
protein relative to incompletely cleaved NC-SP2 products in recombinant viruses carrying wild-type or 
A431V mutated NC/SP2 sequences, was proportional to virus infectivity, whether in the presence (a 
measure of resistance) or in the absence (a measure of fitness) of protease inhibitor lopinavir. 
Regarding the importance of improving cleavage at the SP2/p6 sites, the mutational studies by   
Coren et al. cited above suggest that cleavage at this site is critical for HIV infectivity. The extent to 
which mutations in SP2/p6, in SP2, or even in NC/SP2, could impact SP2/p6 cleavage and release of 
mature p6 protein is unclear. In the Nijhuis et al. study [41], where viruses carrying substitutions at 
positions 436 and 437 within SP2 were studied, these mutations appeared to decrease the amounts of 
an incompletely cleaved NC-SP2-p6 intermediate product, but their effect on the amounts of mature p6 
protein was not seen.  
The third unanswered question is to understand how improved cleavage by the protease can 
produce resistance, independently of changes in fitness. One possibility is that a better substrate will 
constitute a better competitor for protease binding in the presence of protease inhibitors. This may 
appear unlikely, especially in view of the fact that affinity of PIs for the HIV protease is several orders 
of magnitude greater (picomolar versus micromolar) than the affinity of Gag cleavage sites [43]. This 
potential balance, however, may be strongly affected by the local concentration of the competing 
partners: the concentration of Gag cleavage sites can be considered as being very high at the site of 
virion assembly, release and maturation, and the intracellular or intravirion concentration of PIs is 
largely unknown. An alternative model has been proposed, according to which Gag cleavage site 
mutations would improve the efficiency of ribosomal frameshift at the Gag-Pol junction, thus 
increasing the amounts of protease [44]. This model, however, remains controversial [45]. Viruses 2010, 2                              
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Figure 4. Resistance-associated modification of contacts between protease and Gag. 
Representation of the NC/SP2 cleavage site (the amino acid backbone and surface 
occupancy are illustrated) within the protease active site. Left: wild-type protease and Gag. 
Right: protease carrying a V82A resistance mutation and Gag harboring the A431V 
mutation. Both views are from above the flap region of protease (top views). The 
backbones of the flaps (residues 47 to 53) are illustrated as a light blue- and a violet ribbon 
above the surface of the cleavage site. The protease residues (Val and Ala for wild type 
and mutated protease, respectively) at position 82 and 82’ in the active site of the enzyme 
are shown. Replacement of Val82’ by the smaller Ala82’ in the resistant protease (bottom 
right of the right panel) results in the loss of contact with the Asn residue in position P1 
(AsnP1) of the cleavage site. This can be partly compensated by the Gag mutation A431V, 
which creates a protrusion in position P2 of the cleavage site (ValP2 on the right panel, in 
red). This is expected to create a new contact with the protease active site (not shown), at a 
position that is not normally occupied by the substrate.  
 
 
8. Role of other mutations or polymorphisms in Gag in HIV resistance to PIs 
Most studies on the role of Gag in resistance to PIs have essentially focused on mutations affecting 
cleavage site sequences in the NC/SP2/p6 region of Gag. In their study establishing the role of 
cleavage site mutations in this region, Dam et al. [40] dismissed a potential role of changes in other 
Gag domains in resistance and/or fitness. Indeed, the phenotype of recombinants carrying only patient-
derived NC/SP2/p6 domains from highly resistant patient-derived viruses did not differ from that of 
recombinants carrying whole patient-derived Gag sequences. Recent data by Parry et al. [46], Viruses 2010, 2                              
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however, also studying Gag sequences from highly resistant primary viruses, clearly demonstrated that 
domains in the matrix (MA) and capsid (CA) protein of HIV-1 were able to confer higher resistance 
and improved replicative capacity to viruses bearing mutations in the protease. Unlike the mechanisms 
discussed above, these changes do not directly target the MA/CA cleavage site. Instead, multiple 
polymorphisms are involved, which could improve fitness and resistance by improved MA/CA 
cleavage through modifications of the overall conformation of the Gag precursor. Two other studies 
have examined the impact of Gag mutations outside of cleavage sites on the fitness of PI-resistant 
viruses [47,48]. Both studies observe that changes in the NC/SP2/p6 region can significantly improve 
fitness of replication-impaired viruses carrying mutations in the protease. These phenomena, in line 
with the observations of Dam et al. on the fitness of viruses in which NC/SP2 mutations had been 
reverted, may again relate to increases in cleavage efficiency by overall conformational changes of this 
region of Gag. 
9. Gag cleavage site mutations in a clinical context: frequency, kinetics of emergence, and impact 
on treatment response in vivo 
Existing data on the frequency of cleavage site mutations in treatment-naïve and -experienced 
patients is limited. Recently Verheyen et al.  [12] explored the prevalence of polymorphisms and 
treatment-associated mutations in the NC/SP2/P6 cleavage sites (431V, 436R, 437V, 449F/H/V, 451T, 
452S, 453A/L) among a large set of therapy naïve patients whose viruses did not carry primary 
resistance mutations (n = 1846). While polymorphisms were relatively frequent, in particular at 
position 449 and 451, the residues involved were clearly distinct from therapy-associated mutations. 
Only three therapy-associated mutations (436R, 453L and 437V) were found in more than 1% of these 
patients (8.5%, 5.7% and 1.7%, respectively). In striking contrast, in a group of therapy naïve patients 
who carried primary PIs resistance mutations (suggesting transmission of a resistant virus) the 431V 
mutation was found at a high frequency (22%), while this mutation did not exceed 0.5% in patients 
from the first group [12]. As in most other studies, the large majority of samples were from subtype-B 
HIV-infected patients. Differences in the prevalence of mutations and polymorphisms were noted 
between subtype-B and non-B viruses, although the limited number of samples from each subtype did 
not allow specific association. This is a relevant issue, since polymorphisms in Gag may facilitate the 
selection of specific protease mutations, by reducing their fitness cost. 
The frequency and the kinetics of emergence of Gag cleavage site mutations during the course of 
evolution of HIV resistance to PIs have not been fully evaluated. Several studies have compared 
treatment-naïve and -experienced patients, and concluded on a higher frequency of mutations in the 
second group. However, to quantify the difference, relatively large cohorts should be considered, and 
group definition should be clearly stated. Verheyen et al. [37] reported that approximately 10% of 
treatment-naïve patients without primary resistance mutations (n = 275) harbored treatment-associated 
mutation(s) in NC/SP2/P6 cleavage sites. In the same study, 60% of treatment-experienced patients 
carrying at least one primary resistance mutation (n = 225) had one or more cleavage site 
mutation [37]. The frequency appears to increase with the duration of exposure to PIs, since highly 
evolved viruses from patients having failed multiple lines of PI-based antiretroviral therapy, carrying 
multiple resistance mutations in the protease and expressing high levels of resistance, almost always Viruses 2010, 2                              
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bear mutations in Gag cleavage sites [38]. It is worth stressing that subtype-B viruses were largely 
prevalent in these studies. The emergence of subtype-specific Gag mutations and their implication in 
resistance development deserve dedicated surveillance, as different solutions for resistance may 
characterize genetically distinct viruses. As an example, a recent study on subtype-G infected patients 
(n = 21) suggested that the frequent polymorphism 453T favored the selection of 453I rather than the 
treatment-associated 453L change observed in subtype-B viruses [49]. 
Because mutations in Gag were until recently essentially considered as fitness compensatory 
changes rather than as true resistance mutations, most resistance genotype assays do not take these 
mutations into account in their interpretation algorithms. These algorithms are for the most part based 
on correlations between response to PI treatment and genotype. Furthermore, if Gag cleavage site 
mutations emerge in the context of heavily mutated protease genes, their individual statistical impact 
on clinical response is likely to be confounded by the overall protease genotype. There are, however, 
some indications that the presence of Gag cleavage site mutations may correlate with virological 
outcome in patients in whom first line PI therapy has failed and in whom salvage therapy involves 
another compound of the same class [35,50]. This further suggests that these mutations not only affect 
viral fitness, but could also act as bona fide resistance mutations. 
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